Ubenimex, the only CD13 inhibitor available, has been used as an immunomodulating adjuvant for treating hematological malignancies; it enhances the killing activity of T- or B-lymphocytes and natural killer cells, but this effect is not related to the regulation of CD13 activity or expression [24, 25]. Here, ANPEP is linked to hematologic disorder.